Annual CFI
$163.29 M
+$57.13 M+53.82%
31 December 2023
Summary:
Allogene Therapeutics annual cash flow from investing activities is currently $163.29 million, with the most recent change of +$57.13 million (+53.82%) on 31 December 2023. During the last 3 years, it has risen by +$668.41 million (+132.33%). ALLO annual CFI is now -0.48% below its all-time high of $164.08 million, reached on 31 December 2019.ALLO Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$75.99 M
-$150.60 M-201.85%
30 September 2024
Summary:
Allogene Therapeutics quarterly cash flow from investing activities is currently -$75.99 million, with the most recent change of -$150.60 million (-201.85%) on 30 September 2024. Over the past year, it has dropped by -$41.73 million (-121.76%). ALLO quarterly CFI is now -167.29% below its all-time high of $112.94 million, reached on 31 March 2023.ALLO Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$88.22 M
-$41.73 M-32.11%
30 September 2024
Summary:
Allogene Therapeutics TTM cash flow from investing activities is currently $88.22 million, with the most recent change of -$41.73 million (-32.11%) on 30 September 2024. Over the past year, it has dropped by -$57.21 million (-39.34%). ALLO TTM CFI is now -63.47% below its all-time high of $241.47 million, reached on 31 March 2023.ALLO TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +53.8% | -121.8% | -39.3% |
| 3 y3 years | +132.3% | -684.0% | -43.7% |
| 5 y5 years | +125.8% | -196.5% | +156.1% |
ALLO Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -0.2% | +132.3% | -167.3% | at low | -63.5% | +98.3% |
| 5 y | 5 years | -0.5% | +125.8% | -167.3% | +82.3% | -63.5% | +117.0% |
| alltime | all time | -0.5% | +125.8% | -167.3% | +82.3% | -63.5% | +113.9% |
Allogene Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$75.99 M(-201.8%) | $88.22 M(-32.1%) |
| June 2024 | - | $74.61 M(+237.1%) | $129.94 M(+79.3%) |
| Mar 2024 | - | $22.13 M(-67.2%) | $72.49 M(-55.6%) |
| Dec 2023 | $163.29 M(+53.8%) | $67.46 M(-296.9%) | $163.29 M(+12.3%) |
| Sept 2023 | - | -$34.27 M(-299.7%) | $145.43 M(-28.9%) |
| June 2023 | - | $17.16 M(-84.8%) | $204.60 M(-15.3%) |
| Mar 2023 | - | $112.94 M(+127.7%) | $241.47 M(+127.5%) |
| Dec 2022 | $106.16 M(-35.1%) | $49.60 M(+99.1%) | $106.16 M(+23.7%) |
| Sept 2022 | - | $24.91 M(-53.9%) | $85.81 M(+16.1%) |
| June 2022 | - | $54.03 M(-341.5%) | $73.92 M(+66.2%) |
| Mar 2022 | - | -$22.38 M(-176.5%) | $44.48 M(-72.8%) |
| Dec 2021 | $163.66 M | $29.25 M(+124.8%) | $163.66 M(+4.5%) |
| Sept 2021 | - | $13.01 M(-47.1%) | $156.62 M(+160.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | $24.59 M(-74.6%) | $60.25 M(-115.3%) |
| Mar 2021 | - | $96.80 M(+335.8%) | -$393.32 M(-22.1%) |
| Dec 2020 | -$505.12 M(-407.8%) | $22.21 M(-126.6%) | -$505.12 M(-2.7%) |
| Sept 2020 | - | -$83.36 M(-80.6%) | -$519.40 M(+45.4%) |
| June 2020 | - | -$428.97 M(+2758.5%) | -$357.27 M(-407.5%) |
| Mar 2020 | - | -$15.01 M(-289.3%) | $116.19 M(-29.2%) |
| Dec 2019 | $164.08 M(-125.9%) | $7.93 M(-89.9%) | $164.08 M(-204.4%) |
| Sept 2019 | - | $78.78 M(+77.1%) | -$157.23 M(-71.6%) |
| June 2019 | - | $44.49 M(+35.3%) | -$552.78 M(-7.9%) |
| Mar 2019 | - | $32.89 M(-110.5%) | -$599.91 M(-5.2%) |
| Dec 2018 | -$632.80 M | -$313.39 M(-1.1%) | -$632.80 M(+98.1%) |
| Sept 2018 | - | -$316.78 M(>+9900.0%) | -$319.41 M(>+9900.0%) |
| June 2018 | - | -$2.63 M(<-9900.0%) | -$2.63 M(<-9900.0%) |
| Mar 2018 | - | $0.00 | $0.00 |
FAQ
- What is Allogene Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Allogene Therapeutics?
- What is Allogene Therapeutics annual CFI year-on-year change?
- What is Allogene Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly CFI year-on-year change?
- What is Allogene Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Allogene Therapeutics?
- What is Allogene Therapeutics TTM CFI year-on-year change?
What is Allogene Therapeutics annual cash flow from investing activities?
The current annual CFI of ALLO is $163.29 M
What is the all time high annual CFI for Allogene Therapeutics?
Allogene Therapeutics all-time high annual cash flow from investing activities is $164.08 M
What is Allogene Therapeutics annual CFI year-on-year change?
Over the past year, ALLO annual cash flow from investing activities has changed by +$57.13 M (+53.82%)
What is Allogene Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of ALLO is -$75.99 M
What is the all time high quarterly CFI for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly cash flow from investing activities is $112.94 M
What is Allogene Therapeutics quarterly CFI year-on-year change?
Over the past year, ALLO quarterly cash flow from investing activities has changed by -$41.73 M (-121.76%)
What is Allogene Therapeutics TTM cash flow from investing activities?
The current TTM CFI of ALLO is $88.22 M
What is the all time high TTM CFI for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM cash flow from investing activities is $241.47 M
What is Allogene Therapeutics TTM CFI year-on-year change?
Over the past year, ALLO TTM cash flow from investing activities has changed by -$57.21 M (-39.34%)